Benkhedda Salim, Bengherbi Nacera, Cherifi Yahia, Ouabdesselam Souhila, Waheed Nabila, Harris Clara M
Cardiology, Cardiology Oncology Collaborative Research Group, Faculty of Family Medicine, University of Algiers Benyoucef Benkhedda, Algiers, DZA.
Radiation Oncology, The Center for Cancer & Blood Disorders, Fort Worth, USA.
Cureus. 2024 Mar 21;16(3):e56647. doi: 10.7759/cureus.56647. eCollection 2024 Mar.
Background Chemotherapy correlates to acute and long-term cardiotoxicity, is reflected clinically by myocardial and vascular endothelial dysfunction, and can cause cardiovascular complications. Thus, early diagnosis of cardiovascular disease in cancer patients undergoing anti-cancer treatment is necessary to enhance long-term survival. Our principal objective in this study was to discern the impact of specific anti-cancer chemotherapeutics and biologics on arterial stiffness alterations before and after the administration. Methods Conducted at Mustafa Bacha University Hospital, Algeria, the study focused on arterial stiffness in anti-cancer chemotherapy patients. Assessments included blood pressure, diabetes, and dyslipidemia, with precise measurements using validated systems, particularly pulse wave velocity (PWV). Various chemotherapy protocols were applied, and statistical analysis with R software (R Foundation for Statistical Computing, Vienna, Austria) maintained a significance level of p=0.05. Key outcomes centered on carotid-femoral PWV and secondary endpoints such as central and peripheral pressures and pulse pressure (PP). Univariate and bivariate analyses were conducted using appropriate statistical tests. Results A comparative prospective observational study was completed on 58 patients (34 women and 24 men; mean age: 52.64 +/- 12.12 years) treated with anti-cancer chemotherapy agents. Our evaluation included a complete clinical exam, electrocardiogram, Doppler echocardiography, and applanation tonometry with arterial stiffness measurement using PWV. Patients presented significantly higher levels of carotid-femoral PWV, regardless of the chosen chemotherapy protocol, with no return to the initial level after one year of stopping treatment (p-value < 0.01). Moreover, this increase was more significant in patients with diabetes and hypertension and patients treated with monoclonal antibodies or intercalants. Conclusion This prospective study shows that chemotherapy patients have elevated arterial stiffness, emphasizing the need to assess PWV and monitor cardiovascular risk factors. PP measurement with PWV could improve risk management.
背景 化疗与急性和长期心脏毒性相关,临床反映为心肌和血管内皮功能障碍,并可导致心血管并发症。因此,对接受抗癌治疗的癌症患者进行心血管疾病的早期诊断对于提高长期生存率至关重要。本研究的主要目的是识别特定抗癌化疗药物和生物制剂在给药前后对动脉僵硬度改变的影响。方法 在阿尔及利亚的穆斯塔法·巴查大学医院进行,该研究聚焦于抗癌化疗患者的动脉僵硬度。评估包括血压、糖尿病和血脂异常,使用经过验证的系统进行精确测量,特别是脉搏波速度(PWV)。应用了各种化疗方案,并使用R软件(奥地利维也纳的R统计计算基金会)进行统计分析,显著性水平设定为p = 0.05。主要结局以颈股PWV为中心,次要终点包括中心和外周压力以及脉压(PP)。使用适当的统计检验进行单变量和双变量分析。结果 对58例接受抗癌化疗药物治疗的患者(34例女性和24例男性;平均年龄:52.64 +/- 12.12岁)完成了一项比较性前瞻性观察研究。我们的评估包括全面的临床检查、心电图、多普勒超声心动图以及使用PWV测量动脉僵硬度的压平式眼压测量法。无论选择何种化疗方案,患者的颈股PWV水平均显著升高,在停止治疗一年后未恢复至初始水平(p值 < 0.01)。此外,这种升高在糖尿病和高血压患者以及接受单克隆抗体或嵌入剂治疗的患者中更为显著。结论 这项前瞻性研究表明,化疗患者的动脉僵硬度升高,强调了评估PWV和监测心血管危险因素的必要性。通过PWV测量PP可改善风险管理。